Mogamulizumab is a type of medication known as a monoclonal antibody. It is designed to target and bind to a specific protein called CCR4, which is found on the surface of certain cancer cells. By attaching to this protein, mogamulizumab can help the immune system recognize and destroy these cancer cells. In this trial, it is being used to treat patients with a type of skin cancer called cutaneous T-cell lymphoma.

Total Skin Electron Beam Therapy (TSEB) is a form of radiation therapy that is used to treat the entire surface of the skin. It involves directing a beam of electrons at the skin to kill cancer cells. This therapy is often used for skin conditions like cutaneous T-cell lymphoma, as it can effectively target cancer cells while minimizing damage to deeper tissues. In this trial, TSEB is combined with mogamulizumab to enhance the treatment’s effectiveness.

Cutaneous T-cell lymphoma – This is a type of cancer that affects T-lymphocytes, a kind of white blood cell, and primarily involves the skin. It often begins with patches or plaques on the skin that may be itchy or scaly. Over time, it can progress to form tumors or spread to other parts of the body, including lymph nodes and internal organs. The disease can vary greatly in its progression, with some cases remaining stable for years and others advancing more rapidly. It is considered a rare disease and includes subtypes such as Mycosis Fungoides and Sézary Syndrome. These subtypes may present with additional symptoms like enlarged lymph nodes or circulating cancerous cells in the blood.